Volume 119, Issue 4 pp. 965-969

Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia

Roman Crazzolara

Roman Crazzolara

Tyrolean Cancer Research Institute (TCRI) at the University of Innsbruck,

Department of Paediatrics, Innsbruck University Hospital, Innsbruck, Austria,

Search for more papers by this author
Karin Jöhrer

Karin Jöhrer

Tyrolean Cancer Research Institute (TCRI) at the University of Innsbruck,

Search for more papers by this author
Ricky W. Johnstone

Ricky W. Johnstone

Gene Regulation Laboratory, Peter MacCallum Cancer Institute, Melbourne, Australia,

Search for more papers by this author
Richard Greil

Richard Greil

Tyrolean Cancer Research Institute (TCRI) at the University of Innsbruck,

Laboratory of Molecular Cytology, Department of Internal Medicine, Innsbruck University Hospital, and

Search for more papers by this author
Reinhard K Ofler

Reinhard K Ofler

Tyrolean Cancer Research Institute (TCRI) at the University of Innsbruck,

Division of Molecular Pathophysiology, Institute of Pathophysiology, University of Innsbruck, Innsbruck, Austria

Search for more papers by this author
Bernhard Meister

Bernhard Meister

Tyrolean Cancer Research Institute (TCRI) at the University of Innsbruck,

Department of Paediatrics, Innsbruck University Hospital, Innsbruck, Austria,

Search for more papers by this author
David Bernhard

David Bernhard

Tyrolean Cancer Research Institute (TCRI) at the University of Innsbruck,

Division of Molecular Pathophysiology, Institute of Pathophysiology, University of Innsbruck, Innsbruck, Austria

Search for more papers by this author
First published: 11 December 2002
Citations: 36
Roman Crazzolara, MD, Department of Paediatrics, Innsbruck University Hospital, Anichstrasse 35, 6020 Innsbruck, Austria. E-mail: [email protected]

Abstract

Summary. The chemokine receptor CXCR4 plays a crucial role in the survival and trafficking of leukaemia cells and requires further attention as human immunodeficiency virus type I (HIV-I) utilises CXCR4 as the major coreceptor for cellular entry. We demonstrated that inhibitors of histone deacetylases, currently being tested in clinical trials for the treatment of various tumours, extensively downregulated CXCR4 protein and mRNA levels in leukaemia cell lines and lymphoblasts from patients with childhood acute leukaemia. As a result, the ability of stromal cell-derived factor-1 to induce cellular migration was impaired. Repression of CXCR4 transcription by inhibitors of histone deacetylases might therefore represent a promising novel approach in the treatment of acute leukaemias.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.